OBJECTIVES: Autosomal dominant polycystic kidney disease (ADPKD) is the most common type of polycystic kidney disease (PKD) and the fourth leading cause of end-stage renal disease. Currently, there is no published information on medical resource utilisation (MRU) in patients with ADPKD in Europe. This study aimed to better understand MRU associated with ADPKD by disease stage in six European countries (Germany, France, the United Kingdom, Italy, Spain and Sweden). METHODS: This study was a retrospective review of medical charts collected via an online physician survey. Participating physicians abstracted data for the last three eligible ADPKD patients treated in their practice, each within a different Chronic Kidney Disease (CKD) stage. Data collected over the past 2 years included socio-demographics, clinical characteristics and MRU, such as diagnostic tests, specialist visits, dialysis, emergency department visits, inpatient admissions and medications.   RESULTS: A total of 1,055 ADPKD patients were enrolled. The mean (SD) age of the sample was 50.4 (14.4) years, 53.6% were male, with 39.4% employed full time. Only 40% of patients had a known PKD genotype, of which 83% had PKD-1 and 17% had PKD-2. Almost all patients (99.1%) experienced at least 1 ADPKD-related complication, most commonly hypertension (75.4%). On average (SD), patients had 4.4 (9.3) annual specialist visits. Approximately 19.7% of patients experienced at least 1 hospitalisation over the 2 year study period with a mean (SD) length of stay of 7.0 (8.5) days.  Patients in more advanced disease stages reported higher mean (SD) annual specialist visits and more disease-related hospitalisations, 1.5 (1.1) and 9.2% in CKD Stage 1 compared to 10.0 (17.2) and 32.4% in Dialysis, respectively.   CONCLUSIONS: This is the first study to provide evidence on MRU among patients with ADPKD in Europe. Results demonstrate that ADPKD patients require substantial MRU, which accumulate with disease progression.